<DOC>
	<DOCNO>NCT01656330</DOCNO>
	<brief_summary>The purpose study ass use 2 different Prothrombin Complex Concentrates ( PCCs ) ability reverse ( normalize ) pharmacodynamic effect rivaroxaban healthy adult volunteer .</brief_summary>
	<brief_title>A Study Assess Effects 2 Different Prothrombin Complex Concentrates Pharmacodynamics Rivaroxaban Healthy Adult Volunteers</brief_title>
	<detailed_description>This single-center , open-label ( volunteer staff know identity treatment ) , randomize ( volunteer assign treatment chance ) study healthy adult volunteer assess effect 2 different Prothrombin Complex Concentrates ( PCCs ) ( drug act control bleed ) pharmacodynamics ( ie , study biochemical physiological effect drug body ) rivaroxaban ( drug act prevent formation blood clot ) . Eligible volunteer receive treatment rivaroxaban administer orally ( mouth ) Days 1-4 . On Day 5 , rivaroxaban administer orally randomize intravenous ( IV ) ( vein ) administration 1 3 treatment : Profilnine SD ( 3-factor PCC ) , Beriplex P/N ( 4-factor PCC ) , saline . Blood sample collect healthy volunteer study assess activity rivaroxaban . Safety monitor throughout study . The total length participation study volunteer approximately 28 day ( include 21-day Screening Period 7-day Treatment Period ) .</detailed_description>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Have coagulation test result PT , INR aPTT within normal limit Have Body Mass Index ( BMI ; weight [ kg ] /height2 [ ] 2 ) 18 30 kg/m2 ( inclusive ) , body weight 50 100 kg Have blood pressure ( volunteer supine [ lie face ] 5 minute ) 90 140 mmHg systolic , inclusive , 50 90 mmHg diastolic Nonsmoker History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic ( blood ) disease , thrombosis , coagulation ( blood clot ) disorder , lipid abnormality , significant pulmonary ( lung ) disease , diabetes mellitus , renal ( kidney ) hepatic ( liver ) insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude volunteer could interfere interpretation study result History serious bleeding past , include gastrointestinal bleeding require hospitalization , intracranial ( brain ) bleeding type , uncontrollable postoperative bleed History intracranial tumor aneurysm know abdominal aneurysm Known allergy study drug excipients formulation Known allergy heparin history heparininduced thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>JNJ-39039039</keyword>
	<keyword>BAY59-7939</keyword>
	<keyword>Prothrombin Complex Concentrate ( PCC )</keyword>
</DOC>